TRIM14在恶性肿瘤中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2018.12.006

摘要/Abstract

摘要： 三重基序蛋白14（TRIM14）是三重基序蛋白家族众多成员之一，具有调控先天免疫反应、影响细胞分化等生理作用。新近研究表明，TRIM14在几种常见肿瘤（非小细胞肺癌、乳腺癌、肝细胞癌、骨肉瘤及口腔鳞状细胞癌）中均有表达，且可通过不同机制影响恶性肿瘤的增殖、浸润、转移、耐药以及肿瘤患者的预后。

关键词: 肿瘤, 细胞增殖, 肿瘤转移, 三重基序蛋白14

Abstract: Tripartite motifcontaining 14 (TRIM14) is a member of tripartite motif family. Regulating innate immune response and affecting cell differentiation are the main physiological functions of TRIM14. It is reported TRIM14 expresses in various tumors such as nonsmall cell lung cancer, breast cancer, hepatocellular carcinoma, osteosarcoma and oral squamous cell carcinoma. The proliferation, invasion, metastasis, drug resistance of malignant tumors and the prognosis of patients with cancer can be affected via different mechanisms of TRIM14.

Key words: Neoplasms, Cell proliferation, Neoplasms metastasis, Tripartite motif-containing 14

杨志贤，侯飞，李浩宇，邓智勇. TRIM14在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(12): 731-734.

Yang Zhixian, Hou Fei, Li Haoyu, Deng Zhiyong. Research progress of TRIM14 in malignant tumors[J]. Journal of International Oncology, 2018, 45(12): 731-734.

参考文献

［1］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［2］ Hirose S, Nishizumi H, Sakano H. Pub, a novel PU.1 binding protein, regulates the transcriptional activity of PU.1［J］. Biochem Biophys Res Commun, 2003, 311(2): 351360. DOI: 10.1016/j.bbrc.2003.09.212. ［3］杨星星, 王凯, 陈晓娟, 等. 线粒体抗病毒信号蛋白(MAVS)在宿主天然免疫信号通路中的调节作用［J］. 生物化学与生物物理进展, 2013, 40(5): 397405. DOI: 10.3724/SP.J.1206.2012.00513. ［4］ Zhou Z, Jia X, Xue Q, et al. TRIM14 is a mitochondrial adaptor that facilitates retinoic acidinducible geneⅠlike receptormediated innate immune response［J］. Proc Natl Acad Sci U S A, 2014, 111(2): E245E254. DOI: 10.1073/pnas.1316941111. ［5］周卓, 贾雪, 薛清华, 等. TRIM14蛋白参与抗病毒天然免疫反应［C］. 第九届全国免疫学学术大会, 2014, 中国山东济南. ［6］ Nenasheva VV, Kovaleva GV, Uryvaev LV, et al. Enhanced expression of trim14 gene suppressed Sindbis virus reproduction and modulated the transcription of a large number of genes of innate immunity［J］. Immunol Res, 2015, 62(3): 255262. DOI: 10.1007/s1202601586531. ［7］ Wang S, Chen Y, Li C, et al. TRIM14 inhibits hepatitis C virus infection by SPRY domaindependent targeted degradation of the viral NS5A protein［J］. Sci Rep, 2016, 6: 323336. DOI: 10.1038/srep32336. ［8］ Tan P, He L, Cui J, et al. Assembly of the WHIPTRIM14PPP6C mitochondrial complex promotes RIGⅠmediated antiviral signaling［J］. Mol Cell, 2017, 68(2): 293307.e5. DOI: 10.1016/j.molcel.2017.09.035. ［9］ Nenasheva VV, Kovaleva GV, Khaidarova NV, et al. Trim14 overexpression causes the same transcriptional changes in mouse embryonic stem cells and human HEK293 cells［J］. In Vitro Cell Dev Biol Anim, 2014, 50(2): 121128. DOI: 10.1007/s1162601396834. ［10］王权, 孙文逵, 施毅. 转录因子PU.1与机体免疫功能的相关性及其研究进展［J］. 医学研究生学报, 2013, 26(10): 10961100. DOI: 10.16571/j.cnki.10088199.2013.10.004. ［11］ Su X, Wang J, Chen W, et al. Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NFkappaB signaling pathway［J］. Oncotarget, 2016, 7(9): 99399950. DOI: 10.18632/oncotarget.6941. ［12］ Wang Y, Lin Z, Sun L, et al. Akt/Ezrin Tyr353/NFkappaB pathway regulates EGFinduced EMT and metastasis in tongue squamous cell carcinoma［J］. Br J Cancer, 2014, 110(3): 695705. DOI: 10.1038/bjc.2013.770. ［13］ Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines［J］. Cancer Res, 2003, 63(9): 21722178. ［14］ Wang X, Guo H, Yao B, et al. miR15b inhibits cancerinitiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer［J］. Oncol Rep, 2017, 37(5): 27202726. DOI: 10.3892/or.2017.5532. ［15］ Wang T, Ren Y, Liu R, et al. miR1955p suppresses the proliferation, migration, and invasion of oral squamous cell carcinoma by targeting TRIM14［J］. Biomed Res Int, 2017, 2017: 7378148. DOI: 10.1155/2017/7378148. ［16］ Xu G, Guo Y, Xu D, et al. TRIM14 regulates cell proliferation and invasion in osteosarcoma via promotion of the AKT signaling pathway［J］. Sci Rep, 2017, 7: 42411. DOI: 10.1038/srep42411. ［17］ Kong L, Schafer G, Bu H, et al. Lamin A/C protein is overexpressed in tissueinvading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway［J］. Carcinogenesis, 2012, 33(4): 751759. DOI: 10.1093/carcin/bgs022. ［18］ Daniele S, Costa B, Zappelli E, et al. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells［J］. Sci Rep, 2015, 5: 9956. DOI: 10.1038/srep09956. ［19］ Shen CC, Cui XY, He Y, et al. High phosphorylation status of AKT/mTOR signal in DESI2reduced pancreatic ductal adenocarcinoma［J］. Pathol Oncol Res, 2015, 21(2): 267272. DOI: 10.1007/s1225301498173. ［20］ Chen J, Bai M, Ning C, et al. Gankyrin facilitates folliclestimulating hormonedriven ovarian cancer cell proliferation through the PI3K/AKT/HIF1alpha/cyclin D1 pathway［J］. Oncogene, 2016, 35(19): 25062517. DOI: 10.1038/onc.2015.316. ［21］ Yu GH, Li AM, Li X, et al. Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NFkappaB signaling pathway［J］. Tumour Biol, 2017, 39(6): 1010428317705572. DOI: 10.1177/1010428317705572. ［22］ Dong B, Zhang W. High levels of TRIM14 are associated with poor prognosis in hepatocellular carcinoma［J］. Oncol Res Treat, 2018, 41(3): 129134. DOI: 10.1159/000485625. ［23］ Hu G, Pen W, Wang M. TRIM14 promotes breast cancer cell proliferation by inhibiting apoptosis［J］. Oncol Res, 2018, In press. DOI: 10.3727/096504018X15214994641786. ［24］ Juin P, Geneste O, Gautier F, et al. Decoding and unlocking the BCL2 dependency of cancer cells［J］. Nat Rev Cancer, 2013, 13(7): 455465. DOI: 10.1038/nrc3538. ［25］ HamacherBrady A, Brady NR. Bax/Bakdependent, Drp1independent targeting of Xlinked inhibitor of apoptosis protein (XIAP) into inner mitochondrial compartments counteracts Smac/DIABLOdependent effector caspase activation［J］. J Biol Chem, 2015, 290(36): 2200522018. DOI: 10.1074/jbc.M115.643064. ［26］ Tai WT, Cheng AL, Shiau CW, et al. Signal transducer and activator of transcription 3 is a major kinaseindependent target of sorafenib in hepatocellular carcinoma［J］. J Hepatol, 2011, 55(5): 10411048. DOI: 10.1016/j.jhep.2011.01.047. ［27］艾美玲. TRIM14通过调控HBP通路抑制非小细胞肺癌细胞生长［D］. 南昌：南昌大学, 2016. ［28］ Ruan HB, Singh JP, Li MD, et al. Cracking the OGlcNAc code in metabolism［J］. Trends Endocrinol Metab, 2013, 24(6): 301309. DOI: 10.1016/j.tem.2013.02.002. ［29］ Yehezkel G, Cohen L, Kliger A, et al. Olinked betaNacetylglucosaminylation (OGlcNAcylation) in primary and metastatic colorectal cancer clones and effect of NacetylbetaDglucosaminidase silencing on cell phenotype and transcriptome［J］. J Biol Chem, 2012, 287(34): 2875528769. DOI: 10.1074/jbc.M112.345546. ［30］ Oikari S, Makkonen K, Deen AJ, et al. Hexosamine biosynthesis in keratinocytes: roles of GFAT and GNPDA enzymes in the maintenance of UDPGlcNAc content and hyaluronan synthesis［J］. Glycobiology, 2016, 26(7): 710722. DOI: 10.1093/glycob/cww019. ［31］ Hai J, Zhu CQ, Wang T, et al. TRIM14 is a putative tumor suppressor and regulator of innate immune response in nonsmall cell lung cancer［J］. Sci Rep, 2017, 7: 39692. DOI: 10.1038/srep39692.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.